Induction and maintenance therapy for lupus nephritis: A systematic review and meta-analysis

Lupus

Volumn 19, Issue 6, 2010, Pages 703-710

  Lee, Y H ^a   Woo, J H ^a   Choi, S J ^a   Ji, J D ^a   Song, G G ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Cyclophosphamide; Lupus nephritis; Meta analysis; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AMENORRHEA; ARTICLE; BIOPSY; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AZATHIOPRINE; BIAS (EPIDEMIOLOGY); CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 77950204511     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309357763     Document Type: Article

References (31)

1. Harley JB, Kelly JA, Kaufman KM Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 2006 ; 28: 119-130. (Pubitemid 44526313)
2. Waldman M., Appel GB Update on the treatment of lupus nephritis. Kidney Int 2006 ; 70: 1403-1412. (Pubitemid 44527309)
3. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL) (1992). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992 ; 19: 473-479.
4. Neumann K., Wallace DJ, Azen C., et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995 ; 25: 47-55.
5. Austin HA, III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986 ; 314: 614-619. (Pubitemid 16132725)
6. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004 ; 13: 366-371. (Pubitemid 38788498)
7. Houssiau FA, Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002 ; 46: 2121-2131.
8. Sabry A., Abo-Zenah H., Medhat T., Sheashaa H., Mahmoud K., El-Huseini A. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. Int Urol Nephrol 2009 ; 41: 153-161.
9. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005 ; 10: 504-510.
10. Appel GB, Contreras G., Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 ; 20: 1103-1112.
11. Ginzler EM, Aranow C. Mycophenolate mofetil in lupus nephritis. Lupus 2005 ; 14: 59-64. (Pubitemid 40216070)
12. Chan TM, Tse KC, Tang CS, Mok MY, Li FK Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005 ; 16: 1076-1084.
13. Hu W., Liu Z., Chen H., et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002 ; 115: 705-709. (Pubitemid 34594285)
14. Wang J., Hu W., Xie H., et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007 ; 16: 707-712. (Pubitemid 47517865)
15. Jadad AR, Moore RA, Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 ; 17: 1-12. (Pubitemid 26120810)
16. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 ; 315 (7109). 629-634. (Pubitemid 27387172)
17. Davey Smith G., Egger M. Meta-analyses of randomised controlled trials. Lancet 1997 ; 350 (9085). 1182.
18. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002 ; 21: 1539-1558.
19. Walsh M., James M., Jayne D., Tonelli M., Manns BJ, Hemmelgarn BR Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2007 ; 2: 968-975. (Pubitemid 47050611)
20. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006 ; 8: R182. (Pubitemid 46306295)
21. Grootscholten C., Ligtenberg G., Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006 ; 70: 732-742. (Pubitemid 44215349)
22. Austin HA, III, Illei GG, Braun MJ, Balow JE Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009 ; 20: 901-911.
23. Houssiau FA, Vasconcelos C., D'Cruz D., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004 ; 50: 3934-3940. (Pubitemid 39643941)
24. Mak A., Cheak AA, Tan JY, Su HC, Ho RC, Lau CS Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009 ; 48: 944-952.
25. Navaneethan SD, Viswanathan G., Strippoli GF Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs 2008 ; 68: 2095-2104.
26. Zhu B., Chen N., Lin Y., et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007 ; 22: 1933-1942. (Pubitemid 47244763)
27. Contreras G., Tozman E., Nahar N., Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005 ; 14 (Suppl 1). s33 - s38. (Pubitemid 40460514)
28. Sahin GM, Sahin S., Kiziltas S., Masatlioglu S., Oguz F., Ergin H. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis. Ren Fail 2008 ; 30: 865-869.
29. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004 ; 350: 971-980. (Pubitemid 38269274)
30. Yee CS, Gordon C., Dostal C., et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004 ; 63: 525-529. (Pubitemid 38530195)
31. Mok CC, Ho CT, Siu YP, et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001 ; 38: 256-264.